


# Chemical Science

rsc.li/chemical-science



ISSN 2041-6539



ROYAL SOCIETY  
OF CHEMISTRY

Celebrating  
IYPT 2019

**EDGE ARTICLE**

Lu-Yuan Li, Long Yi, Zhen Xi *et al.*

Dual-biomarker-triggered fluorescence probes for differentiating cancer cells and revealing synergistic antioxidant effects under oxidative stress

Cite this: *Chem. Sci.*, 2019, 10, 1945

All publication charges for this article have been paid for by the Royal Society of Chemistry

## Dual-biomarker-triggered fluorescence probes for differentiating cancer cells and revealing synergistic antioxidant effects under oxidative stress†

Changyu Zhang,<sup>‡a</sup> Qiang-Zhe Zhang,<sup>‡b</sup> Kun Zhang,<sup>‡b</sup> Lu-Yuan Li,<sup>\*b</sup> Michael D. Pluth,<sup>‡c</sup> Long Yi<sup>‡\*a</sup> and Zhen Xi<sup>\*d</sup>

Hydrogen sulfide (H<sub>2</sub>S) and human NAD(P)H:quinine oxidoreductase 1 (hNQO1) are potential cancer biomarkers and also vital participants in cellular redox homeostasis. Simultaneous detection of these two biomarkers would benefit the diagnostic precision of related cancers and could also help to investigate their crosstalk in response to oxidative stress. Despite this importance, fluorescent probes that can be activated by the dual action of H<sub>2</sub>S detection and hNQO1 activity have not been investigated. To this end, dual-biomarker-triggered fluorescent probes 1 and 2 were rationally constructed by installing two chemoselective triggering groups into one fluorophore. Probe 1 provides a small turn-on fluorescence response toward H<sub>2</sub>S but a much larger response to both H<sub>2</sub>S and hNQO1 in tandem. By contrast, fluorescence probe 2 is activated only in the presence of both H<sub>2</sub>S and hNQO1. Probe 2 exhibits a large fluorescence turn-on (>400 fold), high sensitivity, excellent selectivity as well as good biocompatibility, enabling the detection of both endogenous H<sub>2</sub>S and hNQO1 activity in living cells. Bioimaging results indicated that probe 2 could differentiate HT29 and HepG2 cancer cells from HCT116, FHC and HeLa cells owing to the existence of relatively high endogenous levels of both biomarkers. Expanded investigations using 2 revealed that cells could generate more endogenous H<sub>2</sub>S and hNQO1 upon exposure to exogenous hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), implying the synergistic antioxidant effects under conditions of cellular oxidative stress.

Received 23rd August 2018  
Accepted 9th January 2019

DOI: 10.1039/c8sc03781g

rsc.li/chemical-science

## Introduction

Cancer, one of the most life-threatening diseases, is characterized as uncontrolled growth and division of normal cells beyond their natural boundaries. The mortality of cancer remains high, which is mainly due to metastasis of primary cancer tumors.<sup>1</sup> The early stages of cancer development carry the maximum potential for therapeutic interventions, and the survival rate of

certain cancers can be significantly improved with early diagnosis and treatment.<sup>2</sup> Cancer biomarkers are endogenous molecules that are differentially expressed in cancer cells relative to their normal counterparts. Altered levels of such biomarkers can be measured to establish a correlation with the disease process and are useful for cancer diagnosis and therapy.<sup>3</sup> Furthermore, the simultaneous detection of multiple biomarkers can significantly increase diagnostic accuracy.<sup>4</sup> Recent research has demonstrated that hydrogen sulfide (H<sub>2</sub>S) and human NAD(P)H:quinine oxidoreductase 1 (hNQO1, EC 1.6.99.2) are potential biomarkers in certain cancer biology, which suggests that fluorescent probes that detect these two species simultaneously would be of significant utility.

As the third endogenous gasotransmitter, H<sub>2</sub>S is enzymatically generated from cystathionine  $\gamma$ -lyase (CSE), cystathionine- $\beta$ -synthase (CBS) and 3-mercaptopyruvate sulfurtransferase (3-MPST)/cysteine aminotransferase (CAT).<sup>5</sup> H<sub>2</sub>S plays important roles in various biological and pathological progress,<sup>6</sup> and misregulation of endogenous H<sub>2</sub>S is associated with numerous diseases.<sup>7</sup> Specially, low levels of endogenous H<sub>2</sub>S appear to exhibit pro-cancer effects, whereas higher concentrations of H<sub>2</sub>S can lead to mitochondrial inhibition and cell death.<sup>8</sup> We note

<sup>a</sup>State Key Laboratory of Organic-Inorganic Composites, Beijing University of Chemical Technology (BUCT), 15 Beisanhuan East Road, Chaoyang District, Beijing 100029, China. E-mail: yilong@mail.buct.edu.cn

<sup>b</sup>State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300071, China. E-mail: liluyuan@nankai.edu.cn

<sup>c</sup>Materials Science Institute, Institute of Molecular Biology, Department of Chemistry and Biochemistry, University of Oregon, Eugene, OR 97403, USA

<sup>d</sup>State Key Laboratory of Elemento-Organic Chemistry, College of Chemistry, National Pesticide Engineering Research Center (Tianjin), Collaborative Innovation Center of Chemical Science and Engineering, Nankai University, China. E-mail: zhenxi@nankai.edu.cn

† Electronic supplementary information (ESI) available: Experimental details, photophysical data and some fluorescence imaging figures. See DOI: 10.1039/c8sc03781g

‡ These authors contributed equally to this work.








Fig. 1 (A) Synthesis route for probe 1. (1)  $\text{POCl}_3$ , DMF, rt, 34%; (2) dimethyl malonate, piperidine, rt, 84%; (3) THF/10% NaOH = 1 : 1, rt, then 1 M HCl, 70%; (4) NBD-PZ, EDCI, DMAP, rt, 67%; (5) DCM/TFA = 1/1, then  $\text{Q}_3\text{PA}$ , EDCI, DMAP, rt, 44%. (B) Synthesis route for probe 2. (1) *N*-Boc-ethylenediamine, reflux, 65%; (2) piperazine, reflux, 63%; (3) NBD-Cl, TEA, rt, 66%; (4) DCM/TFA = 1/1, then  $\text{Q}_3\text{PA}$ , EDCI, DMAP, rt, 88%.

prepared from a simple four-step synthesis from commercial available reagents (Fig. 1B). 4-Bromo-1,8-naphthalic anhydride was refluxed with *N*-boc-ethylenediamine to produce **8**, after which the piperazinyl group was introduced through a nucleophilic substitution to form **9**. Further reaction with NBD-Cl afforded **10**, which was then deprotected and coupled with the  $\text{Q}_3\text{PA}$  motif to provide probe **2** in good yield. All compounds were characterized by  $^1\text{H}$  and  $^{13}\text{C}\{^1\text{H}\}$  NMR spectroscopy as well as high-resolution mass spectrometry (HRMS) (see ESI $^\dagger$ ).

With the probes in hand, we examined the optical response of **1** toward  $\text{H}_2\text{S}$  and hNQO1 in phosphate buffered saline (PBS, 50 mM, pH 7.4 containing 0.007% BSA, 100  $\mu\text{M}$  NADH). As shown in Fig. S1, $^\dagger$  **1** displayed two absorption maxima around 405 nm and 500 nm due to the coumarin and NBD amine moieties, respectively. After reaction with both  $\text{H}_2\text{S}$  and hNQO1, new peaks appeared at 395 and 520 nm, which corresponded to the production of coumarin fluorophore and NBD-SH, respectively. $^{19b}$  Notably, **1** remained water-soluble at concentrations over 25  $\mu\text{M}$  (Fig. S2 $^\dagger$ ). Prior to activation, **1** was essentially non-fluorescent ( $\Phi_1 = 0.15\%$ ) due to the PET-FRET dual-quenching effect. After treatment with both hNQO1 (1  $\mu\text{g mL}^{-1}$ ) and  $\text{H}_2\text{S}$  (200  $\mu\text{M}$ ) for 2 h, a large increase in emission (220-fold) appeared at 465 nm (Fig. 2A). When **1** was treated by  $\text{H}_2\text{S}$  alone for 2 h, only a 34-fold fluorescence enhancement was observed (Fig. 2B), which was far lower than the response from hNQO1 and  $\text{H}_2\text{S}$  together. When **1** was treated with hNQO1 alone for 2 h, the emission enhancement was negligible (2-fold) (Fig. 2C), implying a more efficient quenching from the NBD moiety in **1**. Stability investigations showed that **1** was stable in PBS buffer in




Fig. 2 Time-dependent fluorescent response of probe **1** (1  $\mu\text{M}$ ) toward  $\text{H}_2\text{S}$  (200  $\mu\text{M}$ ) and/or hNQO1 (1  $\mu\text{g mL}^{-1}$ ). (A) **1** was treated with  $\text{H}_2\text{S}$  and hNQO1 simultaneously, or only with  $\text{H}_2\text{S}$  (B) or hNQO1 (C). (D) Time-dependent emissions at 465 nm for **1** treated with hNQO1 and  $\text{H}_2\text{S}$  (black), hNQO1 (green),  $\text{H}_2\text{S}$  (red) or probe **1** alone (blue) in PBS buffer.

the absence of analytes (Fig. 2D). Taken together, probe **1** can be used to detect  $\text{H}_2\text{S}$  and hNQO1 in tandem, whereas treatment with only one of the analytes resulted in a significantly smaller response.

To achieve a more efficient single- and dual-quenching effect, we next assessed the fluorescence response of **2** toward  $\text{H}_2\text{S}$  and/or hNQO1. Emission spectra were also recorded in PBS buffer in the presence of NADH. As shown in Fig. 3A, **2** ( $\Phi_2 = 0.041\%$ ) was essentially non-fluorescent due to the dual-




Fig. 3 Time-dependent fluorescent response of probe **2** (1  $\mu\text{M}$ ) toward  $\text{H}_2\text{S}$  (200  $\mu\text{M}$ ) and/or hNQO1 (1  $\mu\text{g mL}^{-1}$ ). (A) **2** was treated with  $\text{H}_2\text{S}$  and hNQO1 simultaneously, or only with hNQO1 (B) or  $\text{H}_2\text{S}$  (C). (D) Time-dependent emissions at 535 nm for **2** treated with hNQO1 and  $\text{H}_2\text{S}$  (black), hNQO1 (green),  $\text{H}_2\text{S}$  (red) or probe **2** alone (blue) in PBS buffer.



quenching effect, but a strong emission at 535 nm was observed when hNQO1 and H<sub>2</sub>S were added simultaneously. After 2 h, the fluorescence increase at 535 nm was over 400-fold. Consistent with our design, treatment of **2** with hNQO1 or H<sub>2</sub>S alone resulted in only a negligible fluorescence enhancement (3- or 7-fold, Fig. 3B–D and S3†). When compared with probe **1**, we found that probe **2** not only resulted in a larger fluorescence turn-on for combined H<sub>2</sub>S/hNQO1 activation, but also exhibited a lower single-analyte response. Because of these positive properties, we utilized probe **2** for subsequent bioimaging investigations.

Encouraged by the primary fluorescence data, we further validated the chemistry associated with the sensing mechanism by using HRMS and UV-vis analysis. We first confirmed the products of both the single- and dual-analyte reactions of **2** with H<sub>2</sub>S and/or hNQO1 with HRMS (Fig. 4 and S4†). Product **11** ( $\Phi_3 = 7.0\%$ ) of the dual activation reaction was observed as  $[M + H]^+$  325.1652 (calcd for C<sub>18</sub>H<sub>21</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup>, 325.1659). The hNQO1-triggered product **12** and H<sub>2</sub>S-triggered product **13** were observed as  $[M + H]^+$  488.1678 (calcd for C<sub>24</sub>H<sub>22</sub>N<sub>7</sub>O<sub>5</sub><sup>+</sup>, 488.1677) and  $[M + K]^+$  595.2301 (calcd for C<sub>32</sub>H<sub>36</sub>KN<sub>4</sub>O<sub>5</sub><sup>+</sup>, 595.2317), respectively. We did not observe the cross reaction side-products (e.g. hNQO1-triggered **13** or H<sub>2</sub>S-triggered **12**) in the MS spectra. We next performed UV-vis experiments to further probe the reaction mechanism. As shown in Fig. S5A,† the absorption spectrum of **2** displayed two maximum absorbance peaks near 350 and 500 nm. After treatment with H<sub>2</sub>S and hNQO1, both of these peaks disappeared and were replaced by peaks at 400 and 520 nm, which corresponded to the fluorophore and NBD-SH, respectively. When H<sub>2</sub>S alone was added, new peaks at 400 and 520 nm were also observed (Fig. S5B†). Furthermore, there was an obvious overlap between the absorbance profile of NBD-PZ and the emission profile of **11**, indicating an intramolecular FRET effect in probe **2** (Fig. S5C†). When **2** was treated by hNQO1 alone, the absorbance peak at

500 nm increased (Fig. S5D†), implying that the PET process was abolished because the PET effect should result in small changes in absorbance spectra.<sup>22</sup> In addition, probe **2** maintained water solubility of over 20 μM under the experimental conditions (Fig. S6†).

To gain more detailed information about the sensitivity of the dual-responsive probe, we incubated **2** with different levels of hNQO1 and H<sub>2</sub>S for 2 h, after which the emission profiles were measured. Probe **2** was first treated with different concentrations of H<sub>2</sub>S (0–200 μM) in the presence of hNQO1 (1 μg mL<sup>-1</sup>). As shown in Fig. 5A and B, the emission at 535 nm was linearly related to the concentrations of H<sub>2</sub>S from 0 to 75 μM. When added to 1 μg mL<sup>-1</sup> hNQO1, a 10 μM H<sub>2</sub>S solution resulted in a 46-fold fluorescence response. Similarly, we treated **2** with various levels of hNQO1 (0.2–1 μg mL<sup>-1</sup>) in the presence of a constant H<sub>2</sub>S concentration (50 μM), and observed a fluorescence enhancement of 180-fold (Fig. 5C).

One major requirement for a fluorescent probe is that it must exhibit a response toward the targeted analytes but not for other competing species. In order to confirm that the turn-on response of **2** was selectively caused by the dual activation of hNQO1 and H<sub>2</sub>S, probe **2** was incubated with different reactive sulfur species (SO<sub>3</sub><sup>2-</sup> and S<sub>2</sub>O<sub>3</sub><sup>2-</sup>), biothiols (Cys, Hcy and GSH) and reactive oxygen species (H<sub>2</sub>O<sub>2</sub> and HClO) in the presence of hNQO1 or H<sub>2</sub>S. As shown in Fig. 5D, only the co-incubation of hNQO1 and biothiols could trigger a very slight fluorescence response (<10-fold, lanes 10–12), which was significantly lower than the response triggered by hNQO1 and H<sub>2</sub>S (>400-fold, lane




Fig. 4 (A) Chemical structures of products from the single or dual reactions of **2** with H<sub>2</sub>S and hNQO1. HRMS spectra of compounds **11** (B), **12** (C) and **13** (D).




Fig. 5 (A) Emission spectra of **2** (1 μM) toward different concentrations of H<sub>2</sub>S (0–200 μM) in the presence of hNQO1 (1 μg mL<sup>-1</sup>). (B) Linear relationship ( $R^2 = 0.999$  up to 75 μM) between the emission at 535 nm from **2** and the concentration of H<sub>2</sub>S. (C) Emission spectra of **2** (1 μM) toward different levels of hNQO1 (0–1 μg mL<sup>-1</sup>) in the presence of H<sub>2</sub>S (50 μM). (D) Emissions at 535 nm of **2** (1 μM) after treatment with various biologically-relevant species. Lane 0, probe **2** alone; lanes 1–7, SO<sub>3</sub><sup>2-</sup> (200 μM), S<sub>2</sub>O<sub>3</sub><sup>2-</sup> (200 μM), Cys (500 μM), Hcy (500 μM), GSH (5 mM), H<sub>2</sub>O<sub>2</sub> (200 μM), HClO (200 μM), respectively, all in the presence of H<sub>2</sub>S (200 μM); lanes 8–14, SO<sub>3</sub><sup>2-</sup> (200 μM), S<sub>2</sub>O<sub>3</sub><sup>2-</sup> (200 μM), Cys (500 μM), Hcy (500 μM), GSH (5 mM), H<sub>2</sub>O<sub>2</sub> (200 μM), HClO (200 μM), respectively, all in the presence of hNQO1 (1 μg mL<sup>-1</sup>); lane 15, H<sub>2</sub>S (200 μM) and hNQO1 (1 μg mL<sup>-1</sup>).



15). No fluorescence increase was observed when  $\text{H}_2\text{O}_2$  or  $\text{HClO}$  was added (lanes 6–7 and 13–14). Furthermore, treatment of **2** with dicoumarol, an hNQO1 inhibitor, resulted in a slower reaction rate than the inhibitor-free controls, confirming the requirement of hNQO1 for probe activation (Fig. S7†).

### Differentiation of cancer cells using the probe **2**

We first evaluated the cytotoxicity of **2** in HT29 cells (human colorectal epithelial cancer cells) by using the methyl thiazolyl tetrazolium (MTT) assay. The results showed that after 2 h of cellular internalization of 33  $\mu\text{M}$  probe, more than 90% of the cells remained viable (Fig. S8†), implying a low cytotoxicity of **2**. The cytotoxicity of **2** was further studied in HEK293A cells (human embryonic kidney cells) by monitoring of adherent cell proliferation through the xCELLigence RTCA system (Fig. S9†). Compound **2** did not show significant cytotoxicity from 0–15  $\mu\text{M}$  after 24 h incubation, and therefore 10  $\mu\text{M}$  of **2** was used for bioimaging experiments. To investigate whether **2** could be employed to distinguish different types of cancer cells, several cell types were chosen as model biological systems. Given the elevated levels of both  $\text{H}_2\text{S}$  and hNQO1 in some colorectal cancer cells, HT29 and HCT116 cells (human colorectal epithelial cancer cell lines) as well as FHC cells (human normal colorectal epithelial cell line) were initially selected.<sup>9c</sup> Then HepG2 cells (human liver cancer cells) with a high level of endogenous  $\text{H}_2\text{S}$  and HeLa cells (human cervical cancer cells) with a low level of endogenous  $\text{H}_2\text{S}$  were also introduced.<sup>8</sup>

We assumed that only the **2**-stained cells with relatively high endogenous levels of both  $\text{H}_2\text{S}$  and hNQO1 would display significant fluorescence. Aligned with this expectation, the confocal fluorescence images showed clearly differentiable responses from the selected cells (Fig. 6A). The fluorescence intensity in HT29 and HepG2 cells was much stronger than that in other cell lines. The relative fluorescence increases in HT29 and HepG2 cells were about 5.3 and 3.7 fold higher than that of other cells (Fig. 6B). The significantly different fluorescence observed in cancerous *versus* non-cancerous cells is consistent with the probe design and suggests that the probe is differentially activated in cancerous *versus* non-cancerous cells.

In control experiments for single biomarker detection, two single-analyte probes NIR- $\text{H}_2\text{S}$  (for  $\text{H}_2\text{S}$  detection)<sup>9c</sup> and NIR-hNQO1 (for hNQO1 detection)<sup>23</sup> developed by us were separately incubated with these cells (Fig. S10†). As shown in Fig. S11,† when cells were treated with NIR- $\text{H}_2\text{S}$ , the HT29, HepG2 and HCT116 cells displayed a fluorescence response, implying the existence of endogenous  $\text{H}_2\text{S}$  in the cells. When cells were incubated with NIR-hNQO1, the observed fluorescence from the HT29 and HepG2 cells was stronger than that from the other three cell lines (Fig. S12†). The results indicated the relatively high endogenous levels of both  $\text{H}_2\text{S}$  and hNQO1 in HT29 and HepG2 cells, which is consistent with the bioimaging results of probe **2**.

To further confirm the dual-activation of **2** in cancer cells, we added aminoxyacetic acid (AOAA, 200  $\mu\text{M}$ ), which is an inhibitor of enzymatic  $\text{H}_2\text{S}$  synthesis, and dicoumarol (100




Fig. 6 Confocal microscopy images for endogenous  $\text{H}_2\text{S}$  and hNQO1 detection in living cells using **2**. (A) Cells ( $\sim 2 \times 10^4$  cells per well) were incubated with only **2** (10  $\mu\text{M}$ ) for 1 h, washed, then imaged. Scale bar, 10  $\mu\text{m}$ . (B) Relative fluorescence intensity of images from (A). (C) Relative fluorescence intensity of images from inhibitor-pretreated HT29 cells.  $N = 3$  fields of cells, error bars are means  $\pm$  sd. \* $P < 0.05$ ; \*\* $P < 0.01$ . For (B), the black \* was relative to HT29 group, and the red \* was relative to HepG2 group.

$\mu\text{M}$ ), which is an hNQO1 inhibitor. For the inhibitor-treated groups, HT29 cells were pretreated with the inhibitor for 30 min, then incubated with **2** (10  $\mu\text{M}$ ) for 1 h, washed and imaged (Fig. S13†). HT29 cells showed strong fluorescence after incubation with **2** alone for 1 h. In contrast, pretreatment of one or two inhibitors led to a significant decrease in fluorescence, and the observed fluorescence intensity was about a half of that in the group without inhibitors (Fig. 6C). These results clearly demonstrated the dual  $\text{H}_2\text{S}$  and hNQO1 requirement for **2**.

### Investigation of the crosstalk between $\text{H}_2\text{S}$ and hNQO1 under oxidative stress

$\text{H}_2\text{O}_2$ , a common ROS, was introduced as a stimulus to investigate the potential crosstalk between  $\text{H}_2\text{S}$  and hNQO1 in cellular redox homeostasis. HeLa cells were selected as the model biological systems due to the relative low levels of the both endogenous biomarkers. The cells were stained by **2**, washed and imaged. As displayed in Fig. 7, **2**-stained HeLa cells exhibited very weak fluorescence. However, a significant fluorescence response was observed when cells were co-incubated with **2** and  $\text{H}_2\text{O}_2$  (50, 100 or 200  $\mu\text{M}$ ) for 1 h. To further understand the results, the inhibitors AOAA and dicoumarol were also used for control experiments (Fig. S14†). The  $\text{H}_2\text{O}_2$ -stimulated cells displayed a significant fluorescence decrease






Fig. 7 Confocal microscopy images for concentration-dependent  $\text{H}_2\text{O}_2$ -induced fluorescence in living HeLa cells using **2**. (A) Cells were co-incubated with probe **2** ( $10 \mu\text{M}$ ) and  $\text{H}_2\text{O}_2$  (0, 50, 100 or  $200 \mu\text{M}$ ) for 1 h, washed and imaged. Scale bar,  $10 \mu\text{m}$ . (B) Relative fluorescence intensity of images versus  $\text{H}_2\text{O}_2$  concentration.  $N = 3$  fields of cells, error bars are means  $\pm$  sd. \* $P < 0.05$ ; \*\* $P < 0.01$ .

when pretreated with one or both inhibitors. The relative emission (Fig. 8A) showed that the stimulation by  $\text{H}_2\text{O}_2$  could trigger about 3.9-fold fluorescence enhancement, which was much higher than the inhibitor-pretreated control groups (about 1.8-fold). In addition, after co-incubation with  $\text{H}_2\text{O}_2$  and **2**, AOAA-pretreated cells were further treated with  $\text{Na}_2\text{S}$  ( $150 \mu\text{M}$ ) for 30 min, and a small increase in fluorescence was observed (1.5 fold) when compared with the AOAA-pretreated control group. These data suggest that endogenous  $\text{H}_2\text{S}$  and hNQO1 could be spontaneously generated in living cells when cells were suffering from acute oxidative stress caused by exogenous  $\text{H}_2\text{O}_2$ .

Based on current knowledge, hNQO1 is regulated by the Keap1 (Kelch-like ECH-associated protein 1)/Nrf2 (nuclear factor-erythroid 2-related factor 2)/ARE (antioxidant response elements) pathway.<sup>10</sup> Nrf2 protein levels can rapidly increase in response to ROS, triggering the expression of hNQO1 to inhibit the formation of free radicals.<sup>15a,24</sup> Meanwhile, elevated Nrf2 can increase the expression of glutathione reductase (GSR), which can reduce GSSG to GSH.<sup>24d,e</sup> Such GSH can be involved in the S-glutathionylation of CBS under  $\text{H}_2\text{O}_2$  to produce CBS-SG, which would enable more efficient biosynthesis of endogenous  $\text{H}_2\text{S}$ .<sup>14b,c</sup> Thus, we propose that the synergistic antioxidant effect of  $\text{H}_2\text{S}$  and hNQO1 for handling oxidative stress in living cells is possibly regulated by Nrf2, which can trigger the expression of hNQO1 directly and improve endogenous  $\text{H}_2\text{S}$  levels indirectly through controlling GSH (Fig. 8B). Taken together, these results support a synergistic antioxidant effect under cellular oxidative stress.




Fig. 8 (A) Relative fluorescence intensity of confocal microscopy images from  $\text{H}_2\text{O}_2$ -induced HeLa cells.  $N = 3$  fields of cells, error bars are means  $\pm$  sd. \* $P < 0.05$ . (B) A proposed mechanism of the synergistic antioxidant effect of  $\text{H}_2\text{S}$  and hNQO1 under oxidative stress.

## Conclusions

In summary, dual-biomarker-triggered fluorescent probes were developed for the simultaneous detection of two potential cancer biomarkers. Probe **1** could detect the two biomarkers with a slight fluorescence response toward one biomarker (34-fold turn-on) and a significantly enhanced fluorescence by dual activation (220-fold turn-on). By contrast, the fluorescence of probe **2** was significantly enhanced and showed a greater response for the dual-activation from  $\text{H}_2\text{S}$  and hNQO1 (>400-fold turn-on). Moreover, probe **2** exhibited high sensitivity, excellent selectivity and good biocompatibility, which enabled us to differentiate activation levels in HT29 and HepG2 cells from FHC, HCT116 and HeLa cells due to the notably different endogenous levels of  $\text{H}_2\text{S}$  and hNQO1 in the cell lines. Importantly, using the probe **2**, we revealed a synergistic antioxidant effect between  $\text{H}_2\text{S}$  and hNQO1 in living cells in response to the oxidative stress. These results clearly demonstrate the strengths of this dual reporter system, including the significant off-on response, ability to distinguish cancer cells with both cancer biomarkers, and ability to investigate the crosstalk of analytes.



We also note, however, potential limitations of this system. For example, the developed tools only provide information on the relative levels of the biomarkers in different cell lines rather than precise quantification measurements. In addition, the development of probes with longer wavelength emissions would be needed to translate these systems into more complex systems, such as animal studies. Based on these needs, we are currently working to develop related dual-responsive probes with emission in the near-infrared region for *in vivo* applications. Overall, our work has demonstrated the research potential of dual-responsive fluorescent probes in cancer biology and intracellular redox homeostasis.

## Conflicts of interest

The authors declare no competing financial interests.

## Acknowledgements

This work was supported by NSFC (21572019, 81672747), 111 project (B14004), and the NIH (R01GM113030).

## Notes and references

- (a) R. L. Siegel, K. D. Miller and A. Jemal, *Ca-Cancer J. Clin.*, 2018, **68**, 7; (b) M. F. Ullah and M. Aatif, *Cancer Treat. Rev.*, 2009, **35**, 193.
- (a) M. Kalinich and D. A. Haber, *Science*, 2018, **359**, 866; (b) P. Sidaway, *Nat. Rev. Clin. Oncol.*, 2017, **14**, 262; (c) S. K. Arya and S. Bhansali, *Chem. Rev.*, 2011, **111**, 6783; (d) M. Gao, F. Yu, C. Lv, J. Choo and L. Chen, *Chem. Soc. Rev.*, 2017, **46**, 2237; (e) S. J. Skates, *Clin. Cancer Res.*, 2016, **22**, 4542.
- (a) S. M. Hanash, S. J. Pitteri and V. M. Faca, *Nature*, 2008, **452**, 571; (b) A. Koch, S. C. Joosten, Z. Feng, T. C. de Ruijter, M. X. Draht, V. Melotte, K. M. Smits, J. Veeck, J. G. Herman, L. V. Neste, W. V. Crieckinge, T. De Meyer and M. Engeland, *Nat. Rev. Clin. Oncol.*, 2018, **15**, 459; (c) E. Billatos, J. L. Vick, M. E. Lenburrg and A. E. Spira, *Clin. Cancer Res.*, 2018, **24**, 2984; (d) A. Chevalier, Y. Zhang, O. M. Khmour, J. B. Kaye and S. M. Hecht, *J. Am. Chem. Soc.*, 2016, **138**, 12009; (e) H. Zhang, J. Fan, J. Wang, B. Dou, F. Zhou, J. Cao, J. Qu, Z. Cao, W. Zhao and X. Peng, *J. Am. Chem. Soc.*, 2013, **135**, 17469; (f) Y. Jiao, J. Yin, H. He, X. Peng, Q. Gao and C. Duan, *J. Am. Chem. Soc.*, 2018, **140**, 5882; (g) K. Gu, Y. Xu, H. Li, Z. Guo, S. Zhu, S. Zhu, P. Shi, T. D. James, H. Tian and W.-H. Zhu, *J. Am. Chem. Soc.*, 2016, **138**, 5334; (h) F. Wang, Y. Zhu, L. Zhou, L. Pan, Z. Cui, Q. Fei, S. Luo, D. Pan, Q. Huang, R. Wang, C. Zhao, H. Tian and C. Fan, *Angew. Chem., Int. Ed.*, 2015, **54**, 7349; (i) X. Zhen, J. Zhang, J. Huang, C. Xie, Q. Miao and K. Pu, *Angew. Chem., Int. Ed.*, 2018, **57**, 7804; (j) X. Chen, D. Lee, S. Yu, G. Kim, S. Lee, Y. Cho, H. Jeong, K. T. Nam and J. Yoon, *Biomaterials*, 2017, **122**, 130.
- (a) C. A. Borrebaeck, *Nat. Rev. Cancer*, 2017, **17**, 199; (b) A. Vargas and C. C. Harris, *Nat. Rev. Cancer*, 2016, **16**, 525.
- (a) L. Li, P. Rose and P. K. Moore, *Annu. Rev. Pharmacol. Toxicol.*, 2011, **51**, 169; (b) C. Szabo, *Nat. Rev. Drug Discovery*, 2007, **6**, 917.
- (a) G. Yang, L. Wu, B. Jiang, W. Yang, J. Qi, K. Cao, Q. Meng, A. K. Mustafa, W. Mu, S. Zhang, S. H. Snyder and R. Wang, *Science*, 2008, **332**, 587; (b) Y.-H. Liu, M. Lu, L.-F. Hu, P. T.-H. Wong, G. D. Webb and J.-S. Bian, *Antioxid. Redox Signaling*, 2012, **17**, 141; (c) J. L. Wallace, J. G. P. Ferraz and M. N. Muscara, *Antioxid. Redox Signaling*, 2012, **17**, 58; (d) A. Papapetropoulos, A. Pyriochou, Z. Altaany, G. Yang, A. Marazioti, Z. Zhou, M. G. Jeschke, L. K. Branski, D. N. Herndon, R. Wang and C. Szabo, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 21972.
- (a) J. L. Wallace and R. Wang, *Nat. Rev. Drug Discovery*, 2015, **14**, 329; (b) L.-F. Hu, M. Lu, P. T. H. Wong and J.-S. Bian, *Antioxid. Redox Signaling*, 2011, **15**, 405; (c) S. Fiorucci, E. Antonelli, A. Mencarelli, S. Orlandi, B. Renga, G. Rizzo, E. Distrutti, V. Shah and A. Morelli, *Hepatology*, 2005, **42**, 539.
- (a) D. Wu, W. Si, M. Wang, S. Lv and A. Ji, *Nitric Oxide*, 2015, **50**, 38; (b) X. Cao, L. Ding, Z. Xie, Y. Yang, M. Whiteman, P. K. Moore and J.-S. Bian, *Antioxid. Redox Signaling*, DOI: 10.1089/ars.2017.7058.
- (a) C. Szabo, C. Coletta, C. Chao, K. Módis, B. Szczesny, A. Papapetropoulos and M. R. Hellmich, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 12474; (b) S. Bhattacharyya, S. Saha, K. Giri, I. R. Lanza, K. S. Nair, N. B. Jennings, C. Rodriguez-Aguayo, G. Lopez-Berestein, E. Basal, A. L. Weaver, D. W. Visscher, W. Cliby, A. K. Sood, R. Bhattacharya and P. Mukherjee, *PLoS One*, 2013, **8**, e79167; (c) K. Zhang, J. Zhang, Z. Xi, L.-Y. Li, X. Gu, Q.-Z. Zhang and L. Yi, *Chem. Sci.*, 2017, **8**, 2776.
- (a) G. Asher, J. Lotem, L. Sachs, C. Kahana and Y. Shaul, *Proc. Natl. Acad. Sci. U. S. A.*, 2002, **99**, 13125; (b) A. T. Dinkova-Kostova and P. Talalay, *Arch. Biochem. Biophys.*, 2010, **501**, 116.
- (a) J. J. Schlager and G. Powis, *Int. J. Cancer*, 1990, **45**, 403; (b) S. Danson, T. H. Ward, J. Butler and M. Ranson, *Cancer Treat. Rev.*, 2004, **30**, 437.
- (a) P. Liu, J. Xu, D. Yan, P. Zhang, F. Zeng, B. Li and S. Wu, *Chem. Commun.*, 2015, **51**, 9567; (b) W. S. Shin, J. Han, P. Verwilt, R. Kumar, J. H. Kim and J. S. Kim, *Bioconjugate Chem.*, 2016, **27**, 1419.
- (a) C. Szabo, *Nat. Rev. Drug Discovery*, 2016, **15**, 185; (b) B. L. Predmore, D. J. Lefter and G. Gojon, *Antioxid. Redox Signaling*, 2012, **17**, 119; (c) Y. Kimura and H. Kimura, *FASEB J.*, 2004, **18**, 1165.
- (a) V. S. Lin, A. R. Lippert and C. J. Chang, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 7131; (b) L. Yi, L. Wei, R. Wang, C. Zhang, J. Zhang, T. Tan and Z. Xi, *Chem.-Eur. J.*, 2015, **21**, 15167; (c) W.-N. Niu, P. K. Yadav, J. Adamec and R. Banerjee, *Antioxid. Redox Signaling*, 2015, **22**, 350.
- (a) D. Ross and D. Siegel, *Curr. Opin. Toxicol.*, 2018, **7**, 67; (b) R. E. Beyer, J. Segura-Aguilar, S. Di Bernardo, M. Cavazzoni, R. Rato, D. Fiorentini, M. C. Galli, M. Setti, L. Landi and G. Lenaz, *Proc. Natl. Acad. Sci. U. S. A.*, 1996, **93**, 2528.
- B. Osborne, N. L. Bentley, M. K. Montgomery and N. Turner, *Free Radicals Biol. Med.*, 2016, **100**, 164.



- 17 For selective reviews: (a) X. Chen, F. Wang, J. Y. Hyun, T. Wei, J. Qiang, X. Ren, I. Shin and J. Yoon, *Chem. Soc. Rev.*, 2016, **45**, 2976; (b) D. Wu, A. C. Sedgwick, T. Gunnlaugsson, E. U. Akkaya, J. Yoon and T. D. James, *Chem. Soc. Rev.*, 2017, **46**, 7015; (c) V. S. Lin, W. Chen, M. Xian and C. J. Chang, *Chem. Soc. Rev.*, 2015, **44**, 4596; (d) M. D. Hartle and M. D. Pluth, *Chem. Soc. Rev.*, 2016, **45**, 6108; (e) H. Zhu, J. Fan, J. Du and X. Peng, *Acc. Chem. Res.*, 2016, **49**, 2115.
- 18 (a) W. Ong, Y. Yang, A. C. Cruciano and R. L. McCarley, *J. Am. Chem. Soc.*, 2008, **130**, 14739; (b) W. C. Silvers, B. Prasai, D. H. Burk, M. L. Brown and R. L. McCarley, *J. Am. Chem. Soc.*, 2013, **135**, 309; (c) S. U. Hettiarachchi, B. Prasai and R. L. McCarley, *J. Am. Chem. Soc.*, 2014, **136**, 7575; (d) G. G. Dias, A. King, F. Moliner, M. Vendrell and E. N. Silva Júnior, *Chem. Soc. Rev.*, 2018, **47**, 12; (e) Y. Qian, J. Karpus, O. Kabil, S. Y. Zhang, H. L. Zhu, R. Banerjee, J. Zhao and C. He, *Nat. Commun.*, 2011, **2**, 495; (f) Y. C. Chen, C. C. Zhu, Z. H. Yang, J. J. Chen, Y. F. He, Y. Jiao, W. J. He, L. Qiu, J. J. Cen and Z. J. Guo, *Angew. Chem., Int. Ed.*, 2013, **52**, 1688; (g) H. A. Henthorn and M. D. Pluth, *J. Am. Chem. Soc.*, 2015, **137**, 15330.
- 19 (a) H. Zhang, C. Zhang, R. Liu, L. Yi and H. Sun, *Chem. Commun.*, 2015, **51**, 2029; (b) C. Zhang, L. Wei, C. Wei, J. Zhang, R. Wang, Z. Xi and L. Yi, *Chem. Commun.*, 2015, **51**, 7505; (c) C. Zhang, R. Wang, L. Chen, B. Li, Z. Xi and L. Yi, *Sci. Rep.*, 2016, **6**, 30148; (d) C. Wei, R. Wang, C. Zhang, G. Xu, Y. Li, Q.-Z. Zhang, L.-Y. Li, L. Yi and Z. Xi, *Chem. – Asian J.*, 2016, **11**, 1376.
- 20 (a) G. C. Van de Bittner, C. R. Bertozzi and C. J. Chang, *J. Am. Chem. Soc.*, 2013, **135**, 1783; (b) A. C. Sedgwick, H.-H. Han, J. E. Gardiner, S. D. Bull, X.-P. He and T. D. James, *Chem. Sci.*, 2018, **9**, 3672; (c) L. Wu, H.-H. Han, L. Liu, J. E. Gardiner, A. C. Sedgwick, C. Huang, S. D. Bull, X.-P. He and T. D. James, *Chem. Commun.*, 2018, **54**, 11336; (d) L. Yuan, W. Lin, Y. Xie, B. Chen and S. Zhu, *J. Am. Chem. Soc.*, 2012, **134**, 1305.
- 21 (a) L. Yi and Z. Xi, *Org. Biomol. Chem.*, 2017, **15**, 3828; (b) C. Wei, L. Wei, Z. Xi and L. Yi, *Tetrahedron Lett.*, 2013, **54**, 6937; (c) L. A. Montoya, T. F. Pearce, R. J. Hansen, L. N. Zakharov and M. D. Pluth, *J. Org. Chem.*, 2013, **78**, 6550.
- 22 L. Yi, H. Li, L. Sun, L. Liu, C. Zhang and Z. Xi, *Angew. Chem., Int. Ed.*, 2009, **48**, 4034.
- 23 C. Zhang, B.-B. Zhai, T. Peng, Z. Zhong, L. Xu, Q.-Z. Zhang, L.-Y. Li, L. Yi and Z. Xi, *Dyes Pigm.*, 2017, **143**, 245.
- 24 (a) P. Nioi and J. D. Hayes, *Mutat. Res.*, 2004, **555**, 149; (b) J. D. Hayes and M. McMahon, *Trends Biochem. Sci.*, 2009, **34**, 176; (c) L. V. Favreau and C. B. Pickett, *J. Biol. Chem.*, 1993, **268**, 19875; (d) K.-A. Jung, B. Choi, C. W. Nam, M. Song, S. T. Kim, J. Lee and M. K. Kwak, *Toxicol. Lett.*, 2013, **218**, 39; (e) J. D. Hayes and A. T. Dinkova-Kostova, *Trends Biochem. Sci.*, 2014, **39**, 199.

